Company opens private waitlist as life sciences organizations look for compliant ways to adopt AI in commercial operations.
MONTRÉAL, QC / ACCESS Newswire / March 12, 2026 / Ask-Nova, an AI assistant built for pharmaceutical, biotechnology, and medical technology sales teams, today announced early access to the platform and opened a private waitlist for select companies. The announcement comes as life sciences organizations increasingly explore how artificial intelligence can support commercial teams while maintaining compliance in regulated environments.
Industry research shows that 93% of life sciences leaders expect investment in AI, data, and digital technologies to increase, yet only about one-third of employees currently have company-approved access to generative AI tools. As a result, many commercial teams are experimenting with consumer AI applications to summarize meetings, prepare for physician visits, or draft reports often outside the governance frameworks required in regulated industries.
Ask-Nova was developed to provide a controlled alternative designed specifically for life sciences commercial workflows and compliance requirements.
The assistant helps field representatives prepare for meetings, capture insights after interactions with healthcare professionals, generate structured summaries, and quickly access product information and supporting clinical evidence while in the field. Designed for mobile use, it allows representatives to quickly access account information, capture notes, and generate summaries directly after customer interactions.
“AI is already finding its way into the day-to-day workflows of commercial teams,” said Dave Scheine, CEO of Ask-Nova. “The challenge for pharmaceutical and med-tech companies is enabling those productivity gains while maintaining the governance and compliance standards required in regulated environments.”
Ask-Nova provides a range of capabilities designed to support field sales teams, including AI-generated call summaries, voice-enabled note capture, proactive account and territory insights, and automated CRM documentation. Additional details about the platform’s capabilities are available at https://ask-nova.ai.
In early pilot programs with pharmaceutical commercial teams, Ask-Nova saw strong adoption among field representatives. The company reports that more than 80% of participants began using the assistant before formal training, with early usage suggesting potential time savings of roughly 30 to 40 minutes per day per representative. Much of that benefit came from faster call preparation, allowing reps to quickly surface relevant account insights, product information, and suggested talking points without navigating multiple CRM and analytics systems.
Ask-Nova combines modern AI capabilities with deep experience in life sciences technology. The company is led by CEO Dave Scheine, formerly of Google and AI customer engagement platform Podium. Product development is led by Ludovic Petit, CEO of Exeevo, who previously held senior roles at Symphony Health and spent more than 15 years at CegedimDendrite (now IQVIA), where he worked on CRM and commercial technology platforms used by pharmaceutical companies.
Companies interested in early access can request an invitation at https://ask-nova.ai.
Ask-Nova Team to Attend Reuters Events Pharma USA 2026
Members of the Ask-Nova team will attend Reuters Events Pharma USA 2026, taking place March 16-17 at the Pennsylvania Convention Center in Philadelphia, where industry leaders will discuss the growing role of artificial intelligence in commercialization and field operations.
About Ask-Nova
Ask-Nova develops AI software for pharmaceutical, biotechnology, and medical technology commercial teams. The platform helps field representatives prepare for meetings, capture insights, generate reports, and access customer intelligence while operating within the compliance and governance requirements expected in regulated healthcare environments. The technology was originally developed within life sciences software provider Exeevo, which is backed by Valsoft Corporation, a global investor focused on vertical market software.
Media Contact
Dave Scheine
CEO, Ask-Nova
[email protected]
https://ask-nova.ai
SOURCE: Ask Nova
